Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Anuja Chatterjee"'
Autor:
Alison Davie, Sory Traoré, Massimo Giovannitti, Giuseppe Pompilio, Mark Lambton, Esra Cakar, Anuja Chatterjee
Publikováno v:
Global & Regional Health Technology Assessment, Vol 10, Iss 1 (2023)
Background: Abemaciclib was recently approved by the European Medicines Agency in combination with adjuvant endocrine therapy (ET) for adult patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−), n
Externí odkaz:
https://doaj.org/article/9ce25b8009594acfa444f2b72eb4cbed
Publikováno v:
BMC Public Health, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Human papillomavirus (HPV) infection is a pre-requisite for cervical cancer, which represents the third most common cancer among women worldwide. A causal relationship also exists between HPV and cancer in other areas of the femal
Externí odkaz:
https://doaj.org/article/c569bc2952de4ee6a12c9fea97606773
Autor:
Nichola R. Naylor, Rifat Atun, Nina Zhu, Kavian Kulasabanathan, Sachin Silva, Anuja Chatterjee, Gwenan M. Knight, Julie V. Robotham
Publikováno v:
Antimicrobial Resistance and Infection Control, Vol 7, Iss 1, Pp 1-17 (2018)
Abstract Background Accurate estimates of the burden of antimicrobial resistance (AMR) are needed to establish the magnitude of this global threat in terms of both health and cost, and to paramaterise cost-effectiveness evaluations of interventions a
Externí odkaz:
https://doaj.org/article/a6ff06cf6ef945b9b9843249f83ff970
Autor:
Hannah Lishman, Paul Aylin, Vivian Alividza, Enrique Castro-Sanchez, Anuja Chatterjee, Victor Mariano, Alan P. Johnson, Samir Jeraj, Céire Costelloe
Publikováno v:
Systematic Reviews, Vol 6, Iss 1, Pp 1-7 (2017)
Abstract Background Antibiotic resistance (ABR) is an urgent problem globally, with overuse and misuse of antibiotics being one of the main drivers of antibiotic-resistant infections. There is increasing evidence that the burden of community-acquired
Externí odkaz:
https://doaj.org/article/9749dd53c0cd43a2947baaaf2d8a46e0
Autor:
Anuja Chatterjee, Gijs van de Wetering, Ron Goeree, Carolyn Owen, Anne Marie Desbois, Stephane Barakat, Beenish S. Manzoor, Kavita Sail
Publikováno v:
PharmacoEconomics - Open. 7:199-216
Venetoclax is a first-in-class targeted therapy option that is an inducer of apoptosis in chronic lymphocytic leukemia (CLL) cells. The open-label phase III CLL14 clinical trial showed that venetoclax combined with obinutuzumab (VEN+O) is superior to
Autor:
Arliene Ravelo, Kavita Sail, Beenish S Manzoor, Gijs van de Wetering, Venetia Qendri, Anuja Chatterjee, Sheila Shapouri, Matthew S. Davids
Publikováno v:
Journal of managed carespecialty pharmacy. 27(11)
BACKGROUND: Chronic lymphocytic leukemia (CLL) is a significant health and economic burden in the United States. Treatments include chemoimmunotherapy, such as obinutuzumab (G) plus chlorambucil (Clb) or bendamustine plus rituximab (BR), and chemothe
Publikováno v:
BMC Public Health, Vol 20, Iss 1, Pp 1-8 (2020)
BMC Public Health
BMC Public Health
Funder: Merck Sharp and Dohme; doi: http://dx.doi.org/10.13039/100009947
Background: Human papillomavirus (HPV) infection is a pre-requisite for cervical cancer, which represents the third most common cancer among women worldwide. A causal relat
Background: Human papillomavirus (HPV) infection is a pre-requisite for cervical cancer, which represents the third most common cancer among women worldwide. A causal relat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2b5ea7979ce972b0a56fb3542ec7828
Autor:
Beenish S Manzoor, Patricia Manzi, Gijs van de Wetering, Anne Marie Desbois, Kavita Sail, Ron Goeree, Carolyn Owen, Anuja Chatterjee
Publikováno v:
Blood. 136:31-32
OBJECTIVES: To estimate the cost-effectiveness of venetoclax + obinutuzumab (GAZYVA®, G), (VEN+G) in the treatment of first-line (1L) chronic lymphocytic leukemia (CLL) from a Canadian health care system cost perspective. METHODS: A three-state part
Publikováno v:
e66
The Lancet Planetary Health, 3(2). Elsevier
The Lancet Planetary Health, 3(2). Elsevier